SCHEMBL13628200

SCHEMBL13628200

O=C(Nc1ccc2c(c1)N(Cc1cc(F)cc3c1OCOC3)C(=O)/C2=N\O)c1ccc(Cl)c(Cl)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 9/20 0.45
MAPT P10636 5/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
KDM4E B2RXH2 2/20 0.40
NPSR1 Q6W5P4 2/20 0.40
ALDH1A1 P00352 2/20 0.40
HPGD P15428 2/20 0.40
LMNA P02545 1/20 0.40
RAB9A P51151 8/20 0.37
MEN1 O00255 4/20 0.37
KMT2A Q03164 4/20 0.37
MAOB P27338 3/20 0.37
POLB P06746 2/20 0.37
PKM P14618 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
EPHA2 P29317 1/20 0.36
KDR P35968 1/20 0.36
EPHB4 P54760 1/20 0.36
NFKB1 P19838 1/20 0.35
HTT P42858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13628197 0.92 NPC1 (0.39) NPC1SMN1; SMN2NPSR1RAB9AMEN1
SCHEMBL13628199 0.90 MAPT (0.40) NPC1MAPTSMN1; SMN2NPSR1ALDH1A1
SCHEMBL13628195 0.90 RPS6KA2 (0.40) NPC1KDM4ENPSR1RAB9APOLB
SCHEMBL13628304 0.89 RAB9A (0.41) NPC1MAPTSMN1; SMN2NPSR1ALDH1A1
SCHEMBL13637629 0.88 MAPT (0.42) NPC1MAPTSMN1; SMN2ALDH1A1LMNA
SCHEMBL13628301 0.88 MAPK8 (0.34) NPC1MAPTNPSR1ALDH1A1RAB9A
SCHEMBL13628170 0.88 MAPT (0.45) NPC1MAPTSMN1; SMN2KDM4ENPSR1
SCHEMBL13637453 0.87 RPS6KA2 (0.42) NPC1MAPTSMN1; SMN2KDM4ENPSR1
SCHEMBL13628198 0.87 KMT2A (0.43) NPC1MAPTKDM4ENPSR1ALDH1A1
SCHEMBL13628201 0.87 RAB9A (0.38) NPC1MAPTSMN1; SMN2NPSR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) MAP3K1, JUN, MAP3K7 NPC1 1715/4885MAPT 1666/4885SMN1; SMN2 3544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.